Cargando…
FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry”
Despite billions of dollars invested in clinical trials to develop novel therapeutics for Alzheimer's disease, no approved treatments have been developed in the past 15 years. In that span, new classes of drugs have been developed and tested, including monoclonal antibodies, γ-secretase modulat...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804505/ https://www.ncbi.nlm.nih.gov/pubmed/31650002 http://dx.doi.org/10.1016/j.trci.2018.11.004 |